MedTrace Logo

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NCT00604786 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-05-10

Study results available
· View outcomes & findings →

Summary

This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies. The investigators predict that cells in the blood will be effected before cells in the nose or skin.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

omalizumab

Dosing is based on IgE level and weight given every 2 or 4 weeks

DRUG

placebo

Dosing is based on IgE level and weight given every 2 or 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Sarbjit S Saini, M.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00604786 on ClinicalTrials.gov